Crossmark

Reply to ‘Use of serum fibroblast growth factor 23 vs. plasma B-type natriuretic peptide levels in assessing the pathophysiology of patients with heart failure’

Crossref DOI link: https://doi.org/10.1038/hr.2017.59

Published Online: 2017-04-27

Published Print: 2017-10-05

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Imazu, Miki

Takahama, Hiroyuki

Kitakaze, Masafumi
License Information

Text and Data Mining valid from 2017-04-27

Version of Record valid from 2017-04-27
More Information

Article History

First Online: 27 April 2017

Competing interests

: HT reports grants from Banyu Life Science Foundation International and The Bayer Scholarship for Cardiovascular Research. MK reports grants from the Japanese government, grants from Japan Heart Foundation, grants from the Japan Cardiovascular Research Foundation, grants and personal fees from Takeda, Astellas, Sanofi, Pfizer, Novartis, Bheringer-Ingerheim, Tanabe-mitubishi, Kyowa-hakko-kirin, Abott and Otsuka independent of the submitted work; personal fees from Daiichi-sankyo, Ono, Bayer, from Kowa, Dainihon-sumitomo, Sawai, MSD, Calpis, Shionogi, Astrazeneca, Asahikasei Med, Novo Nordisk, Fuji-film RI and Japan Medical Data, which were independent of the submitted work; and grants from Nihon Kohden. The remaining author declares no conflict of interest.

Free to read: This content has been made available to all.

Document is current

Any future updates will be listed below